Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016
Published Jul 27, 2016
137 pages — Published Jul 27, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
- The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identi

  
Source:
Document ID
GMDHC8308IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Post-Traumatic Stress Disorder (PTSD) Overview101
Therapeutics Development112
  Pipeline Products for Post-Traumatic Stress Disorder (PTSD) Overview111
  Pipeline Products for Post-Traumatic Stress Disorder (PTSD) Comparative Analysis121
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Development by Companies132
Post-Traumatic Stress Disorder (PTSD) Therapeutics under Investigation by Universities/Institutes151
Post-Traumatic Stress Disorder (PTSD) Pipeline Products Glance164
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
  Unknown Stage Products191
Post-Traumatic Stress Disorder (PTSD) Products under Development by Companies202
Post-Traumatic Stress Disorder (PTSD) Products under Investigation by Universities/Institutes221
Post-Traumatic Stress Disorder (PTSD) Companies Involved in Therapeutics Development2320
  Addex Therapeutics Ltd231
  Amorsa Therapeutics Inc.241
  Azevan Pharmaceuticals, Inc.251
  Bionomics Limited261
  Catalyst Pharmaceuticals, Inc.271
  Eli Lilly and Company281
  Humanetics Corporation291
  Intra-Cellular Therapies, Inc.301
  INVENT Pharmaceuticals, Inc.311
  Marinus Pharmaceuticals, Inc.321
  Neuralstem, Inc.331
  NeuroNascent, Inc.341
  Omeros Corporation351
  Otsuka Holdings Co., Ltd.361
  Polleo Pharma Limited371
  Pragma Therapeutics381
  Synchroneuron Inc.391
  Tonix Pharmaceuticals Holding Corp.401
  TRImaran Pharma, Inc.411
  Turing Pharmaceuticals AG421
Post-Traumatic Stress Disorder (PTSD) Therapeutics Assessment4311
  Assessment by Monotherapy Products431
  Assessment by Target443
  Assessment by Mechanism of Action473
  Assessment by Route of Administration502
  Assessment by Molecule Type522
Drug Profiles5468
  acamprosate calcium SR Drug Profile542
  ADX-71743 Drug Profile561
  AM-3506 Drug Profile571
  BNC-210 Drug Profile583
  brexpiprazole Drug Profile616
  CPP-115 Drug Profile674
  D-473 Drug Profile711
  ganaxolone Drug Profile725
  HL-9001 Drug Profile771
  IC-87201 Drug Profile781
  INV-107 Drug Profile791
  INV-170 Drug Profile801
  ITI-007 Drug Profile818
  KDAC-0001 Drug Profile891
  ketamine hydrochloride Drug Profile901
  modafinil Drug Profile911
  NNI-351 Drug Profile921
  NSI-189 Drug Profile934
  PGT-117 Drug Profile971
  Rycal Drug Profile981
  S-107 Drug Profile991
  Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile1001
  Small Molecule to Target GPR151 for CNS Diseases Drug Profile1011
  Small Molecule to Target GPR83 for CNS and Immunological Disorders Drug Profile1021
  Small Molecules for Post-Traumatic Stress Disorder Drug Profile1031
  Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders Drug Profile1041
  Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile1051
  Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder Drug Profile1061
  SRX-246 Drug Profile1072
  Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder Drug Profile1091
  TNX-102 Drug Profile1109
  URB-694 Drug Profile1191
  Vaccine for CNS Disorders Drug Profile1201
  ZL-006 Drug Profile1211
Post-Traumatic Stress Disorder (PTSD) Dormant Projects1222
Post-Traumatic Stress Disorder (PTSD) Discontinued Products1241
Post-Traumatic Stress Disorder (PTSD) Product Development Milestones12511
  Featured News &Press Releases1251
    Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder1251
    Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases1251
    Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention1261
    May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting1261
    May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting1271
    May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)1281
    Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting1291
    Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder1301
    Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC2101301
    Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder1311
    Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation1321
    Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium1331
    May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR1341
    May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry1341
    Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder1342
Appendix1362
  Methodology1361
  Coverage1361
  Secondary Research1361
  Primary Research1361
  Expert Panel Validation1361
  Contact Us1361
  Disclaimer1371

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Post-Traumatic-Stress-Disorder-PTSD-Pipeline-Review-H2-2016-2088-16272>
  
APA:
Global Markets Direct - Market Research. (2016). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Post-Traumatic-Stress-Disorder-PTSD-Pipeline-Review-H2-2016-2088-16272>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.